New Diabetes Drug Approved for Once a Week Dosage

.

New Diabetes Drug Approved for Once a Week Dosage

It has been recently revealed in a report that the new proposal of Amylin Pharmaceutical company for a more convenient and novel type of diabetes drug has been approved by the Food and Drug Administration. This shall now give way for a new type of Type 2 diabetes drug, which can be conveniently registered to people merely once a week and this would be able to give the people a better control over their disease and they would be able to live life happily and without any fears.

The name of the drug is Byudereon and this will be able to provide help to people suffering from diabetes, only by being administered once a week. There is a competitor drug for the same being developed by Novo Nordisk medical firm, and the name of this drug is Victoza, which shall also be injected once a day.

It has also been rumored that the celebrity chef Paula Deen is going to be the ambassador for their drug, who has apparently recently been diagnosed of diabetes herself.

"Think for a moment how much easier their lives would be by taking a drug just once a week, a drug that offers solid glucose control, does not require glucose monitoring and comes with added benefit of weight loss", revealed David Kliff, publisher of Diabetic Investor.

There is need for the patients of the disease to stay focused on maintaining a healthy life, with good habits of food and exercise. This alone can let them lead a healthy and balanced life, with no types of physical problems ahead of them. People with diabetes need to restrict and control their eating habits, in order to maintain the balance.


Latest News

Rise in Russian Arms Sales In spite of a Drop Globally
PetSmart Sells itself with an $8.3Billion Deal
Falling Oil Prices Result in a Drop in Stocks
Shares of Amaya Fall Due to Probe Conducted by Securities Regulators
Americans Consumers Display Confidence In the Market with Gain in Sales
It’s Time to Hurry Up to Enrol in the First Phase of Affordable Care Act Health
After Merger with Alliance Boots,	Walgreen CEO will Retire
Falling Fuel Prices Lift Airline Profits But No Respite in Fares Expected
Citigroup to Pay Likely $2.7B as Legal Charge
Michael Jeffries Retires as the CEO of Abercrombie & Fitch
Deutsche Bank in Trouble Again in the U.S. for Alleged Tax Scheme
Popular Demand Brings French Toast Crunch Back on the Shelves